Pharmacogenomics

Related References

Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic statement of CYP3A4: relationship to genetic polymorphism in the 5’-upstream regulatory region. Biochem Biophys Res Commun 1999;259:201-205. [PubMed]

Ball SE, Scatina A, Kao J, Ferron GM, Fruncillo R et al. Population distribution and effects on drug metabolism of a genetic variant in the 5’ promoter region of CYP3A4. Clin Pharmacol Ther 1999;66:288-294. [PubMed]

Sata F, Sapone AE, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000;67:48-56. [PubMed]

Fellay J, Marzolini C, Greub G, et al: Predictive Power of P-Glycoprotein and CYP2D6 Polymorphisms for Plasma Levels of Antiretroviral Agents. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL 2001; 260:119 (Abstract)

Paulussen A, Lavrijsen K, Boherts H, et al: Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans. Pharmacogenetics 2000; 10:415-424.(Abstract). [PubMed]

Von Moltke LL, Tran TH, Cotreau MM, Greenblatt DJ. Unusually low clearance of two CYP3A4 substrates, alprazolam and trazodone, in a volunteer subject with wild-type CYP3A promoter region. J Clin Pharmacol 2000;40:200-204. [PubMed]

Rivory LP,Qin H, Clarke SJ, Eris J, Duggin G, Ray E, Trent RJ, Bishop JF. Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporine clearance. Eur J Clin Pharmacol 2000;56:395-398. [PubMed]